SEC Comment Letter for Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Mar 30, 2020

Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: March 30, 2020 · CIK: 0001541157 · Accession: 0000000000-20-002747

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-237389

Date

March 30, 2020

Author

Clive Richardson

Form

UPLOAD

Company

Akari Therapeutics Plc (AKTX) (CIK 0001541157)

Letter

March 30, 2020 Clive Richardson Chief Executive Officer and Chief Operating Officer Akari Therapeutics Plc 75/76 Wimpole Street London W1G 9RT United Kingdom Re:Akari Therapeutics Plc Registration Statement on Form F-3 Filed March 26, 2020 File No. 333-237389 Dear Mr. Richardson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Bass - McDermott Will & Emery LLP

Show Raw Text

March 30, 2020
Clive Richardson
Chief Executive Officer and Chief Operating Officer
Akari Therapeutics Plc
75/76 Wimpole Street
London W1G 9RT
United Kingdom
Re:Akari Therapeutics Plc
Registration Statement on Form F-3
Filed March 26, 2020
File No. 333-237389
Dear Mr. Richardson:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Richard Bass - McDermott Will & Emery LLP

SecProbe.io